Two Big-Hit Breast Cancer Drug Trials Add to AstraZeneca’s Streak

Finding results in a space where its rivals have consistently fallen short, British drugmaker AstraZeneca (AZ) is proudly touting the success of two of its experimental breast cancer drugs in separate clinical trials. The first, capivasertib, rose to meet both of its goals in a phase-3 trial consisting of breast cancer patients...